Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $130.1 million.

  • Arrowhead Pharmaceuticals' Accumulated Expenses rose 11898.79% to $130.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $130.1 million, marking a year-over-year increase of 11898.79%. This contributed to the annual value of $90.4 million for FY2025, which is 4348.35% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Accumulated Expenses stood at $130.1 million, which was up 11898.79% from $90.4 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Accumulated Expenses' 5-year high stood at $130.1 million during Q4 2025, with a 5-year trough of $12.9 million in Q1 2021.
  • Its 5-year average for Accumulated Expenses is $48.1 million, with a median of $43.2 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 23466.18% in 2022, then tumbled by 1513.79% in 2023.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Accumulated Expenses stood at $18.5 million in 2021, then surged by 160.15% to $48.2 million in 2022, then dropped by 3.26% to $46.6 million in 2023, then rose by 27.46% to $59.4 million in 2024, then surged by 118.99% to $130.1 million in 2025.
  • Its Accumulated Expenses stands at $130.1 million for Q4 2025, versus $90.4 million for Q3 2025 and $64.8 million for Q2 2025.